EBNA promoter usage in EBV-negative burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain

International Journal of Cancer

Volumn 93, Issue 5, 2001, Pages 714-719

  Maeda, Akihiko ^a   Kiss, Csaba ^b   Chen, Fu ^b   Ehlin Henriksson, Barbro ^b   Nagy, Noémi ^a   Szekely, Laszlo ^a   Takada, Kenzo ^b   Klein, Eva ^b   Klein, George ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Burkitt lymphoma; EBV; Latent infection; Promoter

Indexed keywords

CELL NUCLEUS ANTIGEN; MEMBRANE PROTEIN; NEOMYCIN;

ARTICLE; BURKITT LYMPHOMA; CELL HYBRIDIZATION; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HERPES VIRUS; HUMAN; HUMAN CELL; INFECTIOUS MONONUCLEOSIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE;

ANTI-BACTERIAL AGENTS; BURKITT LYMPHOMA; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; DRUG RESISTANCE, MICROBIAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; NEOMYCIN; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 0035452476     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1387     Document Type: Article

References (49)

1. EBV-NK cells interactions and lymphoproliferafive disorders
2. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes
3. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1
4. A novel form of Epstein-Barr virus latency in normal B cells in vivo
5. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes
6. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
7. Epstein-Barr virus and its replication
8. Epstein-Barr virus
9. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein
10. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines
11. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: Cell phenotype dependence of virus promoter usage
12. Visualization of alternative Epstein-Barr virus expression programs by fluorescent in situ hybridization at the cell level
13. Differential activation of cytotoxic responses by Burkitt's lymphoma (BL)-cell lines: Relationship to the BL-cell surface phenotype
14. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection
15. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells
16. Epstein-Barr virus infection of human gastric carcinoma cells: Implication of the existence of a new virus receptor different from CD21
17. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lyric cycle
18. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene
19. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease
20. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells
21. Paired Epstein-Barr virus (EBV)-negative and EBV-converted Burkitt lymphoma lines: Stimulatory capacity in allogeneic mixed lymphocyte cultures
22. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: Lack of correlation with EBNA 1 gene transcription in group I Burkitt's lymphoma cell lines
23. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael
24. Inducibility of the Epstein-Bart virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines
25. Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains
26. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle
27. Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro
28. Lymphoma development in mice and humans: Diversity of initiation is followed by convergent cytogenetic evolution
29. Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: Proposal for a new scenario
30. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups
31. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75)
32. Establishment and characterization of a human EBV-negative B cell line (MN 60)
33. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma
34. Induction of plasmacytoid differentiation by phorbol ester in B-cell lymphoma cell lines bearing 8;14 translocations
35. 9-Alkyl anthracyclines. Absence of cross-resistance to Adriamycin in human and murine cell cultures
36. Tumor-associated antigens in human myeloma
37. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes
38. Morphologic variations in human leukemic lymphoblasts (CCRF-CEM cells) after long-term culture and exposure to chemotherapeutic agents. A study with the electron microscope
39. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters. SB-2
40. Release of platelet-activating factor (PAF)-like material from human lymphoid cell lines
41. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma
42. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia
43. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells)
44. Cultured human leukemic non-T/non-B lymphoblasts and their stimulating capacity in "one-way" mixed lymphocyte reaction: Suggestive evidence for early T-cell or B-cell precursors
45. Establishment and characterization of a human histiocytic lymphoma cell line (U-937)
46. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors
47. Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines
48. Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach
49. Characterization of seven newly established nasopharyngeal carcinoma cell lines